Detailed Information
Cited 6 time in 
Cited 7 time in 
Cited 7 time in
Metadata Downloads
Comparison of MOG and AQP4 antibody seroprevalence in Korean adults with inflammatory demyelinating CNS diseases
- Authors
- Hyun, Jae-Won; Lee, Hye Lim; Jeong, Woo Kyo; Lee, Hye Jung; Shin, Jong Hwa; Min, Ju-Hong; Kim, Byoung Joon; Kim, Seung Woo; Shin, Ha Young; Oh, Jeeyoung; Kim, Woojun; Shin, Hyun-June; Oh, Sun-Young; Kim, Hyunjin; Lim, Young-Min; Huh, So-Young; Cho, Eun Bin; Nam, Tai-Seung; Lee, Seung-Han; Kim, Sun-Young; Kang, Sa-Yoon; Han, Suk Geun; Sohn, Eun Hee; Baek, Seol-Hee; Kim, Byung-Jo; Lee, Sang-Soo; Seok, Jin Myoung; Hong, Yoon-Ho; Oh, Seong-il; Kim, Jong Kuk; Shin, Kyong Jin; Kwon, Ohyun; Cho, Joong-Yang; Bae, Jong Seok; Kim, So Yeon; Kim, Yeseul; Lee, Min Young; Kim, Su-Hyun; Kim, Ho Jin
- Issue Date
- May-2021
- Publisher
- SAGE PUBLICATIONS LTD
- Keywords
- Aquaporin-4; myelin oligodendrocyte glycoprotein; prevalence; adult
- Citation
- MULTIPLE SCLEROSIS JOURNAL, v.27, no.6, pp.964 - 967
- Indexed
- SCIE
SCOPUS
- Journal Title
- MULTIPLE SCLEROSIS JOURNAL
- Volume
- 27
- Number
- 6
- Start Page
- 964
- End Page
- 967
- ISSN
- 1352-4585
- Abstract
- We aimed to compare seroprevalence of anti-myelin oligodendrocyte glycoprotein (MOG) and anti-aquaporin-4 (AQP4) antibodies in Korean adults with inflammatory demyelinating diseases (IDDs) of the central nervous system (CNS), based on a multicenter nationwide database. Sera were analyzed using a live cell-based assay for MOG and AQP4 antibodies. Of 586 Korean adults with IDDs of the CNS, 36 (6.1%) and 185 (31.6%) tested positive for MOG and AQP4 antibodies, respectively. No participant showed double positivity. Seroprevalence of MOG antibodies was about five times lower than that of AQP4 antibodies in a large cohort of Korean adults with IDDs of the CNS.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medicine > Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.